# #24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more

**Channel:** Peter Attia MD
**Upload Date:** 2020-01-01
**URL:** https://www.youtube.com/watch?v=ttQY5J98Iok
**Duration:** 89 minutes

## Description

Original release date: 10/19/2018

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter’s most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part V, Peter and Tom talk about inflammation, endothelial health, and oxidative stress as they pertain to cardiovascular disease, and our attempts to monitor them using biomarkers. They also discuss a couple of very important risk factors that too few people (and doctors) know about. Tom closes the five-part series with a tragic story about his good friend that is likely all-too-common for many practicing physicians, that both haunts and motivates Dr. Dayspring to learn as much as he can about the number one killer in the United States.

We discuss:

-Lp(a) [2:30];
-Inflammation [17:15];
-Oxidative stress markers: Lp-PLA2 and oxLDL [20:45];
-Endothelial health markers: ADMA and SDMA [34:30];
-Remnants [43:45];
-Omega-3 fatty acids (EPA and DHA) and apoC-III [55:30];
-Red blood cells and cholesterol transport [1:07:45];
-Tom’s friend Earl [1:10:00];
-Peter’s friend JP [1:18:15]; and
-More.

Show notes page: https://peterattiamd.com/tomdayspring5/

About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 10 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. 

Peter is the founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City, focusing on the applied science of longevity. The practice applies nutritional biochemistry, exercise physiology, sleep physiology, techniques to increase distress tolerance, lipidology, pharmacology, and four-system endocrinology to increase lifespan (delaying the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://peterattiamd.com/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Play: http://bit.ly/TheDriveGooglePlay

## AI Summary

Here's a comprehensive analysis of this episode of The Drive podcast with Dr. Tom Dayspring:

1. **Executive Summary**:
This is the fifth and final episode in a series with Dr. Tom Dayspring focusing on advanced lipidology. The discussion covers LP(a), inflammation, oxidized LDL, remnants, and various biomarkers. The episode provides deep insights into the complexities of lipid metabolism and cardiovascular disease prevention, with particular emphasis on emerging therapeutic approaches and biomarker interpretation.

2. **Key Medical/Scientific Points**:
- LP(a) particles are not effectively lowered by statins but can be reduced by PCSK9 inhibitors [02:25]
- Red blood cells carry more cholesterol molecules than lipoproteins but don't cause atherosclerosis due to inability to penetrate arterial walls [1:09:04]
- APO C3 is a significant predictor of longevity and cardiovascular outcomes [54:15]
- DHA appears more effective than EPA at lowering APO C3 levels [55:52]

3. **Health Optimization Tips**:
Universal Recommendations:
- Consider measuring red blood cell omega-3 levels rather than plasma levels [57:37]
- Focus on particle numbers rather than just cholesterol content [05:50]

4. **Supplements & Medications**:
- EPA/DHA supplements discussed:
  - Carlson's and Nordic Naturals mentioned as quality brands [1:00:39]
  - Different forms (esterified vs. free fatty acids) affect bioavailability [1:03:40]

5. **Biomarkers & Testing**:
- LP(a) particle number is more informative than LP(a) mass [04:04]
- Red blood cell omega-3 index recommended over plasma measurements [57:37]
- ADMA/SDMA as markers of endothelial function [43:12]

6. **Notable Quotes**:
"The field is infinitely more complex than you ever imagined" [1:26:48]

7. **References & Resources**:
- Dr. Bill Harris mentioned as omega-3 expert [59:25]
- Upcoming EPA outcomes trial results expected November (at time of recording) [1:03:40]

8. **Follow-up Questions**:
1. What is the optimal ratio of EPA to DHA for cardiovascular protection?
2. How does APO C3 inhibition affect other metabolic parameters?
3. What is the relationship between LP(a) and inflammation?

This analysis captures the main points but there's significantly more detail in the full transcript. Would you like me to expand on any particular aspect?
